A Systematic Review of the Epidemiology and Disease Burden of Congenital and Immune-Mediated Thrombotic Thrombocytopenic Purpura

被引:2
|
作者
Du, Ping [1 ]
Cristarella, Tiffany [2 ]
Goyer, Camille [2 ]
Moride, Yola [2 ,3 ]
机构
[1] Takeda Dev Ctr Amer Inc, Global Evidence & Outcomes, Cambridge, MA 02142 USA
[2] YolaRX Consultants Inc, Montreal, PQ, Canada
[3] Rutgers State Univ, Ctr Pharmacoepidemiol & Treatment Sci, New Brunswick, NJ USA
来源
JOURNAL OF BLOOD MEDICINE | 2024年 / 15卷
关键词
thrombotic thrombocytopenic purpura; epidemiology; burden of illness; disease management; patient-reported outcomes; ADAMTS13; THERAPEUTIC PLASMA-EXCHANGE; FRENCH NATIONAL REGISTRY; SEVERE ADAMTS13 DEFICIENCY; SINGLE-CENTER EXPERIENCE; CLINICAL CHARACTERISTICS; HIGH PREVALENCE; ADULT PATIENTS; OUTCOMES; TTP; MANAGEMENT;
D O I
10.2147/JBM.S464365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Congenital (cTTP) and immune-mediated (iTTP) thrombotic thrombocytopenic purpura are serious and rare clotting disorders resulting from a deficiency in the ADAMTS13 enzyme. A systematic review was conducted using the Ovid (R) MEDLINE & Embase databases to synthesize the epidemiology and burden of cTTP and iTTP worldwide (from January 1, 2010, to February 6, 2020, with an update that covered the period January 1, 2020-February 11, 2022). Outcomes of interest were incidence and prevalence of TTP, incidence of acute episodes, mortality, burden of illness (eg complications, healthcare utilization, patient-reported outcomes) and disease management. A total of 221 eligible observational studies were included. The incidence rate of acute episodes ranged from 0.19-0.35 person-years in adult patients with cTTP, and 1.81-3.93 per million persons per year for iTTP in the general population. Triggers of acute episodes were similar for cTTP and iTTP, with pregnancy and infection the most commonly observed. Exacerbation in patients with iTTP varied widely, ranging from 2.4-63.1%. All-cause mortality was observed in 0-13.4% of patients with cTTP, across studies and follow-up periods, and in 1.1% (median follow-up: 0.4 years) to 18.8% (1 year) of patients with iTTP during acute episodes. Cardiovascular, renal, and neurological disease were common complications. TTP also led to work disturbances, feelings of anxiety and depression, and general activity impairment. TTP treatment regimens used were generally reflective of current treatment guidelines. The evidence identified describes a high patient burden, highlighting the need for effective treatment regimens leading to improvements in outcomes. Considerable evidence gaps exist, particularly for disease epidemiology, patient-reported outcomes, costs of disease management, and associated healthcare resource utilization. This review may help increase disease awareness and highlights the need for additional real-world studies, particularly in geographical regions outside the United States and Western Europe.
引用
收藏
页码:363 / 386
页数:24
相关论文
共 50 条
  • [31] Efficacy and Safety of Azathioprine during Remission of Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Bichard, Christian
    Mancini, Ilaria
    Agosti, Pasquale
    De Leo, Pasqualina
    Artoni, Andrea
    Capecchi, Marco
    Trisolini, Silvia Maria
    Fozza, Claudio
    Peyvandi, Flora
    BLOOD, 2021, 138
  • [32] Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura
    Kuehne, Lucas
    Kaufeld, Jessica
    Voelker, Linus A.
    Wendt, Ralph
    Schoenermarck, Ulf
    Haegele, Holger
    Osterholt, Thomas
    Eichenauer, Dennis A.
    Bieringer, Markus
    Bergwelt-Baildon, Anke
    Fischereder, Michael
    Buxhofer-Ausch, Veronika
    Menne, Jan
    Brinkkoetter, Paul T.
    Knoebl, Paul
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (04) : 951 - 960
  • [33] Identification of a novel genetic locus associated with immune-mediated thrombotic thrombocytopenic purpura
    Stubbs, Matthew J.
    Coppo, Paul
    Cheshire, Chris
    Veyradier, Agnes
    Dufek, Stephanie
    Levine, Adam P.
    Thomas, Mari
    Patel, Vaksha
    Connolly, John O.
    Hubank, Michael
    Benhamou, Ygal
    Galicier, Lionel
    Poullin, Pascale
    Kleta, Robert
    Gale, Daniel P.
    Stanescu, Horia
    Scully, Marie A.
    HAEMATOLOGICA, 2022, 107 (03) : 574 - 582
  • [34] Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod, Adrien
    Veyradier, Agnes
    Coppo, Paul
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (01) : 58 - 67
  • [35] IMMUNE-MEDIATED ENDOTHELIAL CELL INJURY IN PATHOGENESIS OF THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
    WALL, RT
    HARKER, LA
    QUADRACCI, LJ
    STRIKER, GE
    CLINICAL RESEARCH, 1977, 25 (03): : A350 - A350
  • [36] Two pregnant women with immune-mediated thrombotic thrombocytopenic purpura: A case report
    Uchida, Akiko
    Tanimura, Kenji
    Sasagawa, Yuki
    Yamada, Hirotaka
    Katayama, Yoshio
    Matsumoto, Masanori
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2023, 49 (12) : 2969 - 2974
  • [37] Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura
    Jérémie Joffre
    Lisa Raia
    Tomas Urbina
    Vincent Bonny
    Paul Gabarre
    Louai Missri
    Jean-Luc Baudel
    Paul Coppo
    Bertrand Guidet
    Eric Maury
    Hafid Ait-Oufella
    Critical Care, 27
  • [38] Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Kuehne, Lucas
    Eichenauer, Dennis A.
    Knoebl, Paul
    Voelker, Linus A.
    Kaufeld, Jessica
    Wendt, Ralph
    Haegele, Holger
    Osterholt, Thomas
    Bieringer, Marcus
    Buxhofer-Ausch, Veronika
    Menne, Jan
    Schoenermarck, Ulf
    Brinkkoetter, Paul
    BLOOD, 2021, 138
  • [39] Reversible skin microvascular hyporeactivity in patients with immune-mediated thrombocytopenic thrombotic purpura
    Joffre, Jeremie
    Raia, Lisa
    Urbina, Tomas
    Bonny, Vincent
    Gabarre, Paul
    Missri, Louai
    Baudel, Jean-Luc
    Coppo, Paul
    Guidet, Bertrand
    Maury, Eric
    Ait-Oufella, Hafid
    CRITICAL CARE, 2023, 27 (01)
  • [40] Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura
    Brodsky, Max A.
    Sukumar, Senthil
    Selvakumar, Sruthi
    Yanek, Lisa
    Hussain, Sarah
    Mazepa, Marshall A.
    Braunstein, Evan M.
    Moliterno, Alison R.
    Kickler, Thomas S.
    Brodsky, Robert A.
    Cataland, Spero R.
    Chaturvedi, Shruti
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (12) : 1587 - 1594